|
Albert F. LoBuglio, M.D., a medical oncologist, has been the Director of the Comprehensive Cancer Center at the University of Alabama at Birmingham since 1983. He graduated from Canisius College and Georgetown University School of Medicine. He received his Internal Medicine training at the University of Pittsburgh and subspecialty (Hematology/Oncology) research and training at Harvard (Thorndike Memorial Laboratories). Dr. LoBuglio has held leadership positions in cancer care and research at Ohio State University and the University of Michigan. His expertise has been sought on numerous National Institutes of Health Study Sections, two terms as a member of the Board of Scientific Councilors at the National Cancer Institute and as a scientific advisory board member for multiple companies involved in biologic therapy.
Dr. LoBuglio has a thirty-year track record of competitively funded human tumor immunology research with a major emphasis on early clinical trials of monoclonal antibodies and vaccines over the past fifteen years. He has extensive experience in the design of early clinical trials with biologic reagents emphasizing translational research with strong laboratory preclinical and early clinical trial observations. His group has considerable expertise in working with genetically engineered targeting reagents, including conjugates with radioisotopes, toxins, drugs, and other antitumor reagents. Although he provides leadership for a large comprehensive cancer center, he continues to see patients and design early clinical trials.
| 